10-K: ImmunityBio's 2024 10-K Filing: ANKTIVA Commercialization and Future Pipeline Drive Growth Strategy

ImmunityBio's 2024 10-K highlights the commercialization of ANKTIVA, strategic collaborations, and the advancement of its immunotherapy pipeline to address cancers and infectious diseases.

Summary

• ImmunityBio's 10-K filing reports on the fiscal year ended December 31, 2024.
• The company is focused on developing next-generation immunotherapies and cancer vaccines.
• A key highlight is the FDA approval and commercial launch of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
• The company is pursuing additional approvals for ANKTIVA in other cancer types, including lung, colorectal, and pancreatic cancer.
• ImmunityBio is also developing cell therapies and vaccine vectors to complement its cytokine fusion protein platform.
• The company has established strategic collaborations with BeiGene and Serum Institute to expand its pipeline and address supply chain issues.
• The filing details the company's financial condition, including a history of operating losses and the need for additional financing.
• The company's strategy includes advancing ANKTIVA's commercialization, accelerating product candidates through registrational intent, refining the pipeline, and expanding collaborations.
• The company is pursuing a BLA submission for the indication of reversal of lymphopenia in patients receiving standard-of-care chemotherapy and/or radiation and for the treatment of locally advanced or metastatic pancreatic cancer.
• The company is also planning to submit an sBLA in 2025 for our innovative treatment targeting BCG-unresponsive NMIBC in the papillary indication.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the FDA approval and commercialization of ANKTIVA are positive, the company's history of operating losses, need for additional financing, and various risks and uncertainties temper the overall outlook.

Positives

• FDA approval and commercial launch of ANKTIVA.
• RMAT designation for ANKTIVA and PD-L1 t-haNK.
• Strategic collaborations with BeiGene and Serum Institute.
• Positive clinical data supporting ANKTIVA's potential in multiple cancer types.
• FDA authorization of EAP for rBCG to address TICE BCG shortage.
• ANKTIVA is now widely accessible to patients through commercial and government insurance programs covering over 240 million lives.
• The MHRA validated and accepted the MAA for review in February 2025, while the EMA accepted the MAA for review in January 2025.

Negatives

• The company has a history of operating losses and expects to continue incurring losses.
• The company needs additional financing to fund operations and commercialize its products.
• The RIPA imposes financial obligations and restrictions on business operations.
• The value of warrants and the revenue interest liability are subject to fluctuations based on stock price and sales projections.
• The company has limited experience as a commercial company.
• The company relies on third parties for clinical trials, manufacturing, and essential services.
• The company is subject to extensive government regulations and may be unable to obtain additional regulatory approvals.
• The company may be unable to obtain, maintain, protect, and enforce patent protection.
• The market price of the company's common stock has been and may continue to be volatile.

Risks

• The company's ability to successfully commercialize ANKTIVA and obtain regulatory approval for other product candidates is uncertain.
• Reliance on third parties for clinical trials, manufacturing, and essential services poses risks.
• The company is subject to extensive government regulations and may be unable to obtain additional regulatory approvals.
• The company may be unable to obtain, maintain, protect, and enforce patent protection.
• The market price of the company's common stock has been and may continue to be volatile.
• The company is party to a public-private partnership regarding its manufacturing facility in Dunkirk, New York, and if it or its counterparties fail to meet the obligations of those agreements, it could materially impact its development, operations and prospects.

Future Outlook

ImmunityBio expects to continue incurring significant expenses as it commercializes ANKTIVA, develops its pipeline, and seeks regulatory approvals. The company anticipates needing additional financing to fund its operations and achieve its strategic goals.

Management Comments

• Founder's Vision: My 35-Year Quest to Change the Paradigm of Cancer Care by Activating the Bodys Immune System and Natural Killer Cells.
• The leadership at the FDA listened to this presentation and subsequently while denying RMAT designation, authorized my request to pursue this hypothesis by performing Phase 1 and Phase 2 clinical trials I termed QUILT QU antum I ntegrative L ifelong T rial across certain indications including first-line and second-line NMIBC, second-line and third-line MCC, second-line and third-line metastatic pancreatic cancer, second-line or greater GBM, third-line metastatic TNBC and third-line metastatic head & neck cancer.

Industry Context

The announcement highlights ImmunityBio's efforts to compete in the rapidly evolving fields of immunotherapy and cancer vaccines, where numerous companies are developing innovative approaches to treat cancer and infectious diseases.

Comparison to Industry Standards

• The document mentions competitors in the cytokine fusion protein space, including Nektar Therapeutics, Neoleukin Therapeutics, Novartis, Roche, Sanofi, and Xencor.
• Competitors in the cancer vaccine space include Achilles Therapeutics, BioNTech SE, Geneos Therapeutics, Hangzhou Neoantigen Therapeutics, Merck, Moderna, and Roche.
• Competitors in the NK cell-based therapy space include Artiva Biotherapeutics Inc., Catamaran Bio Inc., Century Therapeutics, Inc., Fate Therapeutics, Inc., Gamida Cell, Ltd., INmune Bio Inc., Nkarta Therapeutics, Inc., NKGen Biotech, Inc., and Shoreline Biosciences, Inc.
• The document compares the median overall survival of 14.1 months in the QUILT 3055 NSCLC trial to the overall survival of 6.1 months for patients who received any therapy post-CPI therapy progression and 7.5 months for patients who received docetaxel plus ramucirumab after initial failure of first-line chemotherapy plus a CPI.

Legal Proceedings

• The company is involved in an arbitration with Shenzhen Beike Biotechnology Co. Ltd. regarding a license agreement.
• The company is subject to a securities class action lawsuit related to the disclosure of an FDA CRL.
• The company is subject to shareholder derivative actions alleging breach of fiduciary duty and unjust enrichment.
• The company was named as a defendant in a lawsuit filed by Exyte, the general contractor for the Dunkirk Facility, in New York state court arising from a construction agreement Exyte entered with Athenex pertaining to construction of the Dunkirk Facility.

Related Party Transactions

• The company has entered into various agreements with related parties, including NantWorks, the Clinic, and Duley Road, for services, leases, and financing.
• Dr. Soon-Shiong, the company's Founder, Executive Chairman and Global Chief Scientific and Medical Officer, has significant interests in these related parties, which may create conflicts of interest.

Stakeholder Impact

• Shareholders: The company's financial performance and stock price are subject to various risks and uncertainties.
• Employees: The company's human resources strategy focuses on attracting, retaining, and developing top talent.
• Customers: The company is committed to addressing critical supply issues and expanding access to high-quality treatments for patients.
• Suppliers: The company relies on third-party CMOs and suppliers for manufacturing and distribution.
• Creditors: The company has significant debt and a revenue interest liability, which could affect its cash flows and ability to raise additional capital.

Next Steps

• Submit a BLA for the indication of reversal of lymphopenia in patients receiving standard-of-care chemotherapy and/or radiation and for the treatment of locally advanced or metastatic pancreatic cancer.
• File an EAP for ANKTIVA and PD-L1 t-haNK in combination with standard of care chemotherapy/radiotherapy and to submit the protocol to the FDA.
• Submit an sBLA in 2025 for our innovative treatment targeting BCG-unresponsive NMIBC in the papillary indication.
• Submit a BLA in 2025 for second-line and third-line treatment of patients with NSCLC, who are progressing on CPIs.
• Expect full enrollment in early 2026 and a data readout in the second half of 2027 for the Non-Small Cell Lung Cancer ResQ201A trial.
• Expect full enrollment in late 2025 to early 2026 with a data readout from the pivotal clinical trial in the second half of 2026 for the BCG-N ave NMIBC with CIS QUILT 2005 trial.
• Target a BLA submission to the FDA in late 2026 to early 2027 for the BCG-N ave NMIBC with CIS QUILT 2005 trial.

Key Dates